Recently, Elon Musk officially announced that his company Neuralink has begun mass production of its brain-computer interface (BCI) devices, marking a significant step from laboratory research toward commercial application. Neuralink’s BCI system—comprising the N1 chip and Link V1 implant—is surgically inserted into the human brain via a minimally invasive procedure, enabling wireless communication between the brain and external devices. The technology aims to help paralyzed patients regain mobility, treat neurological disorders, and potentially enable ‘mind-controlled’ computers or even cognitive enhancement in the future. Musk stated that initial deployments will focus on medical applications and have already received approval from the U.S. Food and Drug Administration (FDA) for human clinical trials. While the potential is vast, experts caution about privacy concerns, ethical implications, and long-term biocompatibility. This move toward mass production not only represents a major milestone for Neuralink but could also herald a new era of human-machine integration.
近日，埃隆·马斯克正式宣布其旗下公司Neuralink已启动脑机接口设备的量产，标志着这一前沿技术从实验室迈向商业化应用的重要一步。Neuralink开发的脑机接口设备名为“N1芯片”与“Link V1”，通过微创手术植入人脑，可实现大脑与外部设备的无线通信。该技术旨在帮助瘫痪患者恢复行动能力、治疗神经系统疾病，甚至未来可能实现“意念控制”计算机或增强人类认知能力。马斯克表示，首批设备将用于医疗用途，并已获得美国食品药品监督管理局（FDA）的批准开展人体临床试验。尽管技术前景广阔，但专家也提醒需关注隐私安全、伦理风险及长期生物相容性等问题。此次量产不仅代表Neuralink的重大突破，也可能开启人机融合的新纪元。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/8812.html